|
|
|
Learn the Benefits of Genetic Testing for Cancer –
now available at Gulf Coast Cancer Centers
We love our families – it’s just in our genes. But our heredity may also be raising a red flag for a few things we don’t love – like a higher risk for certain cancers.
Genetic testing for hereditary breast, colorectal and skin cancers is now available at Gulf Coast Cancer Centers. And peace of mind is closer than you think.
The benefits of genetic testing can help you make more informed decisions about options for early cancer detection and risk reduction. Even if you've already been diagnosed with cancer, genetic testing can provide important information about your risk for a second cancer, helping you and your doctor determine the most effective medical management strategy for you.
Genetic testing also provides important information to your family members, such as inherited gene mutations that increase the risk for cancer and the chance your parents, brothers and sisters or children might have these mutations, too. Click here for our family history questionnaire for common hereditary cancer.
For more information regarding genetic testing for early detection of cancer, call Dr. William Hixson at 866.970.GCCC (4222).
Red Flags
- Personal or family history of breast or ovarian cancer before age 50
- Personal or family history of ovarian cancer at any age
- Family history of two or more primary diagnoses of breast and/or ovarian cancer
- Personal or family history of male breast cancer
- Relatives of patients with a confirmed BRCA-1 or BRCA-2 gene mutation
- Ashkenazi Jewish descent
BRACAnalysis® is a genetic test for hereditary breast and ovarian cancer and assesses a woman’s risk for developing these cancers. This simple blood test, which detects mutations in the BRCA1 and BRCA2 genes, has become the standard of care in identifying individuals with hereditary breast and ovarian cancer.
Red Flags:
- Personal or family history of HNPCC, or hereditary nonpolyposis colorectal cancer; FAP, or familial adenomatous polyposis; AFAP, attenuated familial adenomatous polyposis; or MAP, or MYH -associated polyposis
- Personal or family history of early-onset (before age 50) colorectal and/or endometrial (uterine) cancer, as well as other related cancers such as: ovarian, stomach, kidney/urinary tract, brain, biliary tract, pancreas, small bowel, and sebaceous adenomas
- Relatives of patients with a confirmed MLH1, MSH2, or MSH6 gene mutation
COLARIS® is a genetic test for hereditary colorectal and endometrial cancer (hereditary nonpolyposis colorectal cancer, HNPCC). COLARIS® detects disease-causing mutations in three genes, MLH1, MSH2 and MSH6, responsible for the majority of HNPCC.
Red Flags:
- Two or more melanoma diagnoses in an individual or family
- Melanoma and pancreatic cancer in an individual or family
- Relatives of patients with a confirmed p16 gene mutation
MELARIS® is a genetic test for hereditary melanoma. This test detects inherited mutations in the p16 gene (also called CDKN2A or INK4A), occurring in up to 40 percent of families with hereditary melanoma. Patient survival is excellent when melanoma is detected at an early stage.
|
|
